Rhumbline Advisers Sells 3,538 Shares of LeMaitre Vascular, Inc. $LMAT

Key Points

• Rhumbline Advisers has reduced its stake in LeMaitre Vascular, Inc. by 4.7%, now owning 72,123 shares worth approximately $6.05 million after selling 3,538 shares in the first quarter.
• Multiple institutional investors have increased their holdings, with Millennium Management LLC boosting its stake by 119.8% and acquiring an additional 115,141 shares.
• LeMaitre Vascular reported earnings per share of $0.60 for the quarter, above analysts’ expectations, and announced a quarterly dividend of $0.20 per share with a yield of 0.9%.

Rhumbline Advisers lowered its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 4.7% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,123 shares of the medical instruments supplier's stock after selling 3,538 shares during the quarter. Rhumbline Advisers owned 0.32% of LeMaitre Vascular worth $6,051,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of LMAT. Millennium Management LLC increased its stake in shares of LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier's stock valued at $17,722,000 after acquiring an additional 115,141 shares in the last quarter. Invesco Ltd. grew its position in LeMaitre Vascular by 34.5% in the 1st quarter. Invesco Ltd. now owns 235,436 shares of the medical instruments supplier's stock valued at $19,753,000 after purchasing an additional 60,438 shares during the period. Goldman Sachs Group Inc. grew its position in LeMaitre Vascular by 27.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier's stock valued at $22,019,000 after purchasing an additional 55,804 shares during the period. Nuveen LLC acquired a new stake in LeMaitre Vascular in the 1st quarter valued at $4,631,000. Finally, Aptus Capital Advisors LLC acquired a new stake in LeMaitre Vascular in the 1st quarter valued at $4,483,000. Institutional investors own 84.64% of the company's stock.

Insider Activity at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 2,500 shares of the business's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the transaction, the director directly owned 2,916 shares of the company's stock, valued at approximately $274,104. The trade was a 46.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John A. Roush sold 6,561 shares of the business's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the transaction, the director directly owned 2,916 shares in the company, valued at $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 120,815 shares of company stock valued at $11,280,206 over the last quarter. Corporate insiders own 9.50% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Cantor Fitzgerald lifted their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target for the company in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $97.60.

LeMaitre Vascular Price Performance

LMAT opened at $92.29 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of 44.80, a P/E/G ratio of 2.42 and a beta of 0.79. The firm's fifty day moving average price is $89.69 and its two-hundred day moving average price is $86.06. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. The company had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm's quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular's payout ratio is 38.83%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.